It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Background
The 2020 cancer report states that breast cancer remains a significant cause of death for females, despite the use of various strategies for early detection and treatment. However, there are still gaps in the fight against this disease. Researchers are exploring the hippo pathway, one of eight significant pathways involved in cancer progression, for potential biomarkers to use in personalized therapeutics.
Methods
The current study used bioinformatic tools such as DEGs analysis, Methsurv, Km Plotter to generate data that can predict molecular biomarkers associated with hippo pathway in breast cancer development and treatment. The protein-protein interaction pathway was generated using the STRING database to find associations of hippo pathway genes with other dysregulated genes in breast cancer datasets. A disease enrichment study was also done to explore the potential of the hippo pathway in various aspects.
Results
LATS2 and FAT4 genes of the hippo pathway have shown an interesting association with overall survival, hypermethylation, genetic alterations, and decreased expression levels in the breast cancer cohort. Our findings suggest that both of these genes are associated with breast cancer progression and diagnosis and can be utilized as predictive biomarkers by oncologists for personalized therapy in patients.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Jamia Millia Islamia, Department of Biotechnology, New Delhi, India (GRID:grid.411818.5) (ISNI:0000 0004 0498 8255)
2 University of Ha’il, Department of Family and Community Medicine, College of Medicine, Ha’il, Saudi Arabia (GRID:grid.443320.2) (ISNI:0000 0004 0608 0056)
3 Jamia Millia Islamia, Department of Biosciences, New Delhi, India (GRID:grid.411818.5) (ISNI:0000 0004 0498 8255)
4 Qassim University, Department of Basic health Sciences, College of Applied Medical Sciences, Buraydah, Saudi Arabia (GRID:grid.412602.3) (ISNI:0000 0000 9421 8094)
5 University of Ha’il, Department of Biochemistry, College of Medicine, Ha’il, Saudi Arabia (GRID:grid.443320.2) (ISNI:0000 0004 0608 0056)
6 University of Ha’il, Department of Ophthalmology, College of Medicine, Ha’il, Saudi Arabia (GRID:grid.443320.2) (ISNI:0000 0004 0608 0056)
7 University of Ha’il, Department of Pathology, College of Medicine, Ha’il, Saudi Arabia (GRID:grid.443320.2) (ISNI:0000 0004 0608 0056)
8 University of Calgary, Department of Biological Sciences, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697)